|
(MoneyNewsWire.Net, July 10, 2017 ) Asia-Pacific Ophthalmology Therapeutics Market was worth $4.24 billion in 2016 and is estimated to grow at a CAGR of 8.5%, to reach $6.37 billion by 2021. Ophthalmology is the branch of medicine that deals with the anatomy, physiology and diseases of eye. Recent advancements in genetics and stem cell biology have brought number of changes to the Ophthalmology Therapeutics Market.
Browse market data tables and in-depth TOC of the Asia-Pacific Ophthalmology Therapeutics Market to 2021 @ http://www.marketdataforecast.com/market-reports/asia-pacific-ophthalmology-therapeutics-market-1109/
Asia-Pacific Ophthalmology Therapeutics is driven by the growing prevalence for vision impairment. According to a recent update by WHO the prevalence of visual impairment is nearly 285 million globally. Of these 246 million people have moderate to severe visual impairment. South-East Asia and Western Pacific accounted for 73% of the total visual impairments. Other major factors driving the growth of market include, increasing awareness about the importance of detecting ophthalmic diseases as early as possible and the availability of efficient diagnostic tools. However, stringent regulatory framework and lack of reimbursement policies are restraining the growth of the market.
Asia-Pacific Ophthalmology Therapeutics is broadly categorized into Indication and End User. Based on indication the market is segmented into Glaucoma, Dry Eye Syndrome, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Macular Edema and Allergic Conjunctivitis. Glaucoma is the largest indication segment accounting for a share of approximately XX%. On the basis of End User, the market is segmented into Hospitals, Eye Clinics, Diagnostic Centres and Patients.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/asia-pacific-ophthalmology-therapeutics-market-1109/request-sample
Geographically, Asia-Pacific Ophthalmology therapeutics market is segmented into various regions namely China, India, Japan, South Korea and Australia. Asia-Pacific is the fastest growing region with a CAGR of xx% during the forecast period. Within Asia-Pacific, Japan is the largest market for Opthalmology therapeutics accounting for a share of approximately 45% followed by China
Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche, Valeant, Regeneron, Santen, Bayer, Senju, Lpath and Eye Gate Pharmaceuticals are the major companies covered in the report.
Avail discount @ http://www.marketdataforecast.com/market-reports/asia-pacific-ophthalmology-therapeutics-market-1109/request-discount
About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
|
